This is a working overview of Dual agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-25 and is reviewed periodically as new material appears.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Approximate composition of the free peptide |
| Molecular weight | Approximately 4813 Da | Calculated for the free base |
| Structural class | Synthetic linear peptide | 39 residues with modified backbone |
| Solubility | Soluble in water and polar solvents | Behavior of the lyophilized solid |
| Typical storage temperature | -20 degrees Celsius or below | Solid form, protected from light |
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Acne is defined by clogged pores and bacteria. According to the American Academy of Dermatology, between 40 and 50 million Americans develop acne each year. Although many associate acne with adolescence, acne can occur at any age, with its causes including heredity, hormones, menstruation, food, and emotional stress. Acne is treated with ingredients like salicylic acid, benzoyl peroxide, and retinoids. Those with inflammatory acne should exfoliate with caution as the procedure may make conditions worse and consult a dermatologist before treatment. Benzoyl peroxide is a drying agent and is typically found in concentrations of 2.5 - 10%.
GTP = 3′,5′-cyclic GMP + diphosphate It is often part of the G protein signaling cascade that is activated by low intracellular calcium levels and inhibited by high intracellular calcium levels. In response to calcium levels, guanylate cyclase synthesizes cGMP from GTP. cGMP keeps cGMP-gated channels open, allowing for the entry of calcium into the cell. Like cAMP, cGMP is an important second messenger that internalizes the message carried by intercellular messengers such as peptide hormones and nitric oxide and can also function as an autocrine signal. Depending on cell type, it can drive adaptive/developmental changes requiring protein synthesis. In smooth muscle, cGMP is the signal for relaxation, and is coupled to many homeostatic mechanisms including regulation of vasodilation, vocal tone, insulin secretion, and peristalsis. Once formed, cGMP can be degraded by phosphodiesterases, which themselves are under different forms of regulation, depending on the tissue.
12 July – Members of the NASUWT teaching union in England vote to stage strike action over pay, with 85.5% of members voting to do so on a 51.9% turnout. 13 July – Data released by NHS England indicates that 7.47 million people were waiting to begin routing hospital treatment in June 2023, an increase from 7.42 million in May. The UK government proposes a 6.5% pay rise for teachers, with the leaders of all four major teaching unions expressing support for the increase, meaning strikes by teachers in England are likely to end. Pradjeet Veadhasa, 17, and Sukhman Shergill, 17, are sentenced to life imprisonment with minimum terms of 18 and 16 years respectively for the June 2022 murder of 16-year-old Ronan Kanda in Wolverhampton, who they stabbed after mistaking him for an enemy. 14 July – The UK Health Security Agency warns that tens of thousands of cases of measles could potentially occur in London because of low vaccination numbers there. A 65-year-old man is charged with the murders of Naomi Hunte, who was stabbed to death in February 2022, and Fiona Holm, who disappeared in June 2023 and whose body has not been found. The UK government approves plans to build a road tunnel near Stonehenge. Following trial and conviction at Portsmouth Crown Court, Sarah Somerton-How and her lover, George Webb, are both sentenced to 11 years imprisonment for wilful neglect and holding a person in slavery or servitude after they kept Somerton-How's husband, who has cerebral palsy and is severely sight impaired, a prisoner in squalid conditions for four years.
=== Oxidative stress === Many algicides produced by bacteria increase reactive oxygen species (ROS), which are highly reactive molecules produced during cell processes such as photosynthesis and respiration inside algal cells. This damages DNA, proteins, and lipids, due to an oxidative chain reaction which produces toxic products that lead to cell death. Algal cells can usually counteract these elevated ROS levels with antioxidants, however excessive or prolonged ROS levels can overwhelm the cell and lead to its death. Oxidative stress can be detected in algae based on elevated levels of malondialdehyde (MDA), which is a marker of lipid peroxidation (where lipids are attacked by oxidants), as well as elevated levels of antioxidants and defence enzymes.
Sources: en.wikipedia.org
== Fascia research == In 2007, Schleip along with Werner Klingler organized the first Fascia Research Congress, sponsored by the National Institute of Health and hosted at Harvard Medical School. The conference was covered in a two-page Science Magazine article titled "Cell Biology Meets Rolfing with a section titled "From Rolfer to Researcher" referring to Schleip's career shift. He has served on the scientific committee for all subsequent congresses (2009, 2012, 2015, 2018, 2022, 2025) and chaired the 2018 and 2022 congresses. He was a founding member of the Fascia Research Society in 2011 and has served on the board of directors since 2020. In 2023 he received the designation of founding director. Schleip is the director of the Fascia Research Group, a research collaboration between the University of Ulm (2007-2019) and the Technical University of Munich (2019-Present). He is co-founder and co-director of the Institute für Angewandte & Integrative Gesundheitsforschung (IAIG), a research institute directed towards applied and integrative health research under the umbrella of the Diploma University of Applied Sciences in Germany (2024–present).
Blood doping agents increase the oxygen-carrying capacity of blood beyond the individual's natural capacity. They are used in endurance sports like long-distance running, cycling, and Nordic skiing. Recombinant human erythropoietin (rhEPO) is one of the most widely known drugs in this class. The Athlete Biological Passport is the only indirect testing method for detection of blood doping.
The flow of heat is governed by equations that are similar to the wave equation used to characterize sound propagation in air. When heat is introduced, it moves at 20 meters per second at 1.8 K through helium II as waves in a phenomenon known as second sound. Helium II also exhibits a creeping effect. When a surface extends past the level of helium II, the helium II moves along the surface, against the force of gravity. Helium II will escape from a vessel that is not sealed by creeping along the sides until it reaches a warmer region where it evaporates. It moves in a 30 nm-thick film regardless of surface material. This film is called a Rollin film and is named after the man who first characterized this trait, Bernard V. Rollin. As a result of this creeping behavior and helium II's ability to leak rapidly through tiny openings, it is very difficult to confine. Unless the container is carefully constructed, the helium II will creep along the surfaces and through valves until it reaches somewhere warmer, where it will evaporate. Waves propagating across a Rollin film are governed by the same equation as gravity waves in shallow water, but rather than gravity, the restoring force is the van der Waals force. These waves are known as third sound.
Xanthoria parietina's extreme resilience has made it a focus of astrobiology and space-exposure research. Lichens are among the most stress-tolerant life forms, and X. parietina, with its strong UV defenses, has been tested for survivability in space and Mars-like conditions. Laboratory experiments simulating outer space conditions (high vacuum, cosmic UV radiation) exposed the lichen to 10–14 days of extreme stress. The lichen survived, remained metabolically active, and resumed growth after treatment, proving its short-term viability in space environments. Laboratory tests have further demonstrated the lichen's extraordinary cold tolerance, with dry samples surviving immersion in liquid nitrogen at temperatures below −182 °C (−295.6 °F). Building on these findings, X. parietina was tested under simulated Martian conditions in a 2023 study. Samples were exposed for 30 days to low pressure, a CO2-rich atmosphere, extreme temperature shifts, and high UV radiation. The lichen's health was monitored using chlorophyll fluorescence and structural analysis. It survived the full 30 days, retained photosynthetic ability, and maintained structural integrity, though UV-exposed samples showed reduced efficiency and some pigment degradation. Given this resilience, researchers suggested X. parietina as a candidate for long-term space exposure, such as on the International Space Station or satellites. A 2024 study further examined X. parietina's physiological resilience under simulated Martian conditions.
=== Pharmacokinetics === Prednisone is absorbed in the gastrointestinal tract and has a half-life of 2–3 hours. It has a volume of distribution of 0.4–1 L/kg. The drug is cleared by hepatic metabolism using cytochrome P450 enzymes. Metabolites are excreted in the bile and urine.
Sources: en.wikipedia.org
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.
Single-receptor agents act predominantly at GLP-1R. Tirzepatide retains activity at GIPR, which is expressed in pancreatic islets, adipose tissue, and the central nervous system. The contribution of each receptor to the overall response is still an area of active study, and the relative weight of GIPR signaling in humans is not fully settled.
The fatty diacid moiety binds serum albumin, which reduces renal filtration of the active peptide. Additional resistance to enzymatic breakdown comes from non-natural residues in the backbone. Together these features produce an apparent half-life of about five days and permit weekly dosing intervals.
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.